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Abstract
Introduction Neoadjuvant chemotherapy has become the
standard of care for the diverse population of women diagnosed
with locally advanced breast cancer. Serum biomarker levels are
increasingly being investigated for their ability to predict therapy
response and aid in the development of individualized treatment
regimens. Multianalyte profiles may offer greater predictive
power for neoadjuvant treatment response than the individual
biomarkers currently in use.
Methods Serum samples were collected from 44 patients
enrolled in a phase I–II, open-label study of liposomal
doxorubicin and paclitaxel in combination with whole breast
hyperthermia for the neoadjuvant treatment of locally advanced
breast cancer (stage IIB or stage III). Samples were collected
prior to each of four rounds of treatment and prior to definitive
surgery. Samples were assayed by Luminex assay for 55 serum
biomarkers, including cancer antigens, growth/angiogenic
factors, apoptosis-related molecules, metastasis-related
molecules, adhesion molecules, adipokines, cytokines,
chemokines, hormones, and other proteins.
Results Biomarker levels were compared retrospectively with
clinical and pathologic treatment responses. Univariate analysis
of the data identified several groups of biomarkers that differed
significantly among treatment outcome groups early in the
course of neoadjuvant chemotherapy. Multivariate statistical
analysis revealed multibiomarker panels that could differentiate
between treatment response groups with high sensitivity and
specificity.
Conclusion We demonstrate here that serum biomarker profiles
may offer predictive power concerning treatment response and
outcome in the neoadjuvant setting. The continued development
of these findings will be of considerable clinical utility in the
design of treatment regimens for individual breast cancer
patients.
Trial registration #NCT00346229.
Introduction
Locally advanced breast cancer (LABC) is a generalized diag-
nosis that includes all stage III disease and a subset of stage
IIB disease [1]. The clinical definition of LABC continues to
evolve and differ among physicians, and now includes nonmet-
astatic T3 or T4 tumors as well as N2/N3 disease involving
cCR = clinical complete response; EGFR = epidermal growth factor receptor; IL = interleukin; LABC = locally advanced breast cancer; MIF = migra-
tion inhibitory factor; MMP = matrix metalloproteinase; NAC = neoadjuvant chemotherapy; pCR = pathologic complete response; TNF = tumor necro-
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limited metastasis [2], thus broadening the already diverse
spectrum of LABC presentations. According to the American
College of Surgeons Data Base, approximately 6% of all US
breast cancer cases present as stage III [3]. This number has
declined dramatically over the past decade due to improved
screening and detection practices. The 5-year relative survival
rate for stage III breast cancer is approximately 50%, com-
pared with 87% for stage I. The median survival for women
with stage III disease is 4.9 years [1].
Neoadjuvant chemotherapy (NAC), the delivery of systemic
chemotherapy prior to surgical resection, has emerged as the
preferred initial component of therapy for patients diagnosed
with LABC in an effort to enhance the prospect of breast-con-
serving surgery and to render inoperable tumors resectable
[4,5]. NAC offers the theoretical advantages of early initiation
of systemic therapy, delivery of drugs through intact vascula-
ture, in vivo assessment of therapy response, and the oppor-
tunity to study the biological effects of chemotherapy [6].
Preoperative systemic chemotherapy may also eradicate dis-
tant micrometastases and thus improve the overall effective-
ness of treatment [7]. Several studies comparing NAC with
more traditional adjuvant chemotherapy have found similar sur-
vival rates between the two options [5,8,9], and the use of
NAC is further supported by findings that delaying surgery for
the administration of chemotherapy does not adversely affect
treatment outcome when compared with adjuvant chemother-
apy [10,11].
A pathologic complete response (pCR) following NAC implies
the absence of residual invasive or in situ disease and corre-
lates strongly with both prolonged disease-free survival and
overall survival [12,13]. A recent review of several randomized
clinical trials of NAC for operable breast cancer reported a
response rate of 49% to 94% with a pCR rate of 4% to 34%
[12]. In patients treated with NAC, 60% to 80% demonstrate
some clinical response with 10% to 20% achieving a clinical
complete response (cCR) [4]. Clinical response, however,
often does not correlate with pathologic response as a full
one-third of patients achieving a cCR are found to have path-
ologic evidence of residual disease [9,14]. Despite these diffi-
culties in assessing response, patients demonstrating
complete clinical or pathologic responses to NAC generally
achieve improved outcomes to overall treatment [14,15].
Accurate modalities for assessing chemotherapy response are
critical to the evaluation and expansion of the use of NAC for
breast cancer. Conventional methods including clinical exami-
nation, mammogram, and breast ultrasound are incorrect in
identifying pCR patients in nearly one-half of all cases [2]. Sev-
eral groups have reported promising results in their attempts
to predict treatment response utilizing unconventional tech-
niques such as diffuse optical spectroscopy and magnetic res-
onance imaging [16,17]. A growing number of investigators
have begun to utilize the preoperative nature of NAC to con-
duct intreatment analyses of molecular markers that may pre-
dict response to therapy. The emergence of new technologies
such as transcriptional and proteomic profiling has greatly
aided such investigations [18,19]. For instance, it has been
reported that mutations in p53 are associated with a lower
response rate following NAC [20,21], while coexpression of
HER-2/Neu and topoisomerse II is associated with greater
response rates [22]. Measurements of the traditional breast
cancer markers CA15-3 and HER-2/Neu, however, have dem-
onstrated only limited predictive value in the NAC setting
[23,24].
In the present study we examine a diverse panel of serum
biomarkers in order to identify individual biomarkers and com-
binations that may be useful in predicting treatment response
early in the course of NAC for the treatment of LABC.
Materials and methods
Patients
Serum samples were collected from patients enrolled in a
phase I–II, open-label study of liposomal doxorubicin (Evacet;
Elan Corp., Stevenage, UK) and paclitaxel (Bristol Myers
Squibb, Princeton, NJ, USA) in combination with whole breast
hyperthermia for the neoadjuvant treatment of LABC (stage IIB
or stage III). This trial required informed consent and was con-
ducted under the approval of the Duke University Institutional
Review Board. Protocol-eligible patients were treated with the
combination of Evacet, paclitaxel, and hyperthermia every 3
weeks. The hyperthermia procedure has been described pre-
viously [25].
Following neoadjuvant therapy, patients received appropriate
surgical removal of their primary breast tumor as well as axillary
lymph node dissection. Immediately after surgery, patients
underwent radiation therapy followed by an additional eight
cycles each of 21-day standard dose cyclophosphamide (600
mg/m2), methotrexate (40 mg/m2), 5-fluorouracil (600 mg/m2)
and appropriate hormonal therapy.
The clinical trial accrued a total of 47 patients. Three patients
were deemed nonevaluable because of failure to complete all
four cycles of the neoadjuvant portion of the trial. The clinical
characteristics of the patient study group are presented in
Table 1.
Collection and storage of blood serum
Serum samples were obtained prior to the start of neoadjuvant
therapy (pretreatment), prior to cycles 2, 3, and 4 of neoadju-
vant therapy, and prior to definitive surgery. Blood was drawn
using standard phlebotomy procedures and was collected
without anticoagulant. Blood was allowed to coagulate for up
to 2 hours at room temperature. Sera were separated by cen-
trifugation, immediately aliquoted, frozen, and stored at -80°C.
No more than two freeze–thaw cycles were allowed for any
sample.Available online http://breast-cancer-research.com/content/10/3/R45
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Multiplexed bead-based immunoassay
The xMAP™ bead-based technology (Luminex Corp., Austin,
TX, USA) permits simultaneous analysis of numerous analytes
in a single sample. Fifty-five bead-based xMAP™ immu-
noassays for a variety of serum biomarkers were utilized in the
present study (Table 2).
Assays for ErbB2, epidermal growth factor receptor (EGFR),
CA 15-3, carcinoembryonic antigen, Cyfra 21-1, CA 19-9, CA
72-4, α-fetoprotein, mesothelin, insulin-like growth factor bind-
ing protein 1, human kallikrein 10, and HE4 were developed in
the UPCI Luminex Core Facility [26]. The inter-assay variability
of each assay was 5% to 11%, and the intra-assay variability
was 2% to 9%. Assays for MMP-2 and MMP-3 were obtained
from R&D Systems (Minneapolis, MN, USA), assays for MIP-
1β, eotaxin, IP-10, IL-2R, IL-1Rα, IL-6R, DR5, TNF-RI, and
TNF-RII were obtained from Invitrogen (Camarillo, CA), and
the remaining assays were obtained from Millipore/Linco
Research (St Charles, MO, USA). Overall, eight different mul-
tiplexed panels were used.
Multiplex analysis
Assays were performed according to the manufacturers' pro-
tocols. Luminex Core Facility assays were performed as
described previously [27]. Samples were analyzed using the
Bio-Plex suspension array system (Bio-Rad Laboratories, Her-
cules, CA, USA). Biomarker expression levels were expressed
as median fluorescent intensities generated by analyzing 50 to
100 microbeads for each analyte in each sample. The concen-
trations of analytes were quantitated from median fluores-
cence intensities using standard curves generated by Bio-Rad
five-parameter curve fitting) to the series of known concentra-
tions for each analyte.
Statistical analysis
Clinical response
The Mann–Whitney nonparametric t test was used to evaluate
the significance of differences in serum biomarker levels
expressed as the median fluorescence intensity between treat-
ment response groups separated by treatment timepoints. The
level of significance was taken as P < 0.05. For multivariate
analysis of biomarker combinations, a CART classification tree
[28-30] diagnostic model was created. The Statistical Analy-
sis System (SAS version 9: SAS Institute, Inc., Cary, NC,
USA) was used to fit the logistic regressions using PROC
LOGISTIC. The best subset for each size panel of analytes
was identified through the brand and bound algorithm of Fur-
nival and Wilson [31]. This algorithm maximizes the score
function over all possible combinations of analytes for any
given size panel. The Statistical Analysis System was also
used to fit the logistic regressions and to identify the best sub-
sets for each size panel of biomarkers. Panels were generated
from size 1 to size 10.
Sensitivities were estimated for specificities of 90%, 95%, and
98% by ranking the predicted fit for each control subject,
determining the cutoff points corresponding to these levels of
specificity, and applying the cutoff points to the ranked predic-
tions for the alternative treatment response group. To minimize
overfitting bias, leave-one-out cross-validation was used. The
MATLAB routines treefit  and treeval  were used. For panel
selection, markers were selected incrementally. Given an
existing subset of the markers, each marker was considered a
potential addition to the panel. We began with no markers and
added until little additional progress was made.
Pathologic response
Within each timepoint of treatment, biomarker expression val-
ues – expressed as the median fluorescence intensity – were
adjusted by the following procedure. Quantile normalization
was performed using the normalize BetweenArrays function
(limma package) in R [32], missing values were filled in using
k-nearest neighbor imputation, and values were log-trans-
formed.
Normalized values were filtered according to a univariate, two-
sided t test. From this filtered set, values were progressively
included and excluded from a stepwise regression model. The
final logistic regression model was then subjected to leave-
one-out cross-validation to assess the predictive value.
Table 1
Clinical characteristics of study patients
Characteristic Number of patients
Patients in study
Total enrolled 47
Total completing treatment 44
Clinical stage pretreatment
Stage IIB 15
Stage IIIA 12
Stage IIIB 16
Clinical response
Complete 12
Partial 20
Stable disease 12
Pathologic response
Complete 4
Partial 23
Stable disease 17Breast Cancer Research    Vol 10 No 3    Nolen et al.
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Results
Multiplex analysis of serum levels of various biomarkers 
in LABC patients receiving neoadjuvant chemotherapy
Of the 44 evaluable patients enrolled in the clinical trial, 12
demonstrated a cCR, 20 demonstrated a clinical partial
response, and 12 had no response. Of the same group, four
patients demonstrated a pCR, 23 demonstrated a pathologic
partial response, and 17 had no response. One patient out of
the total 44 did not have blood drawn prior to the second cycle
of NAC and was excluded from the analysis for that timepoint.
A bead-based 55-biomarker panel was utilized to screen the
sera from patients. The biomarkers included cancer antigens,
growth/angiogenic factors, apoptosis-related molecules,
metastasis-related molecules, adhesion molecules, adipok-
ines, cytokines, chemokines, hormones, proteases, and other
proteins (Table 2). Biomarker levels were compared at each
treatment timepoint between complete responders, partial
responders, and nonresponders within each response classi-
fication (clinical or pathologic).
Combinations of biomarkers were evaluated by multivariate
analysis for the ability to predict a particular response. Our
analysis was limited to serum samples collected prior to the
initiation of NAC and prior to the second cycle of therapy. We
did not identify any significant correlations between biomarker
levels and pathologic response at the pretreatment timepoint.
Analysis of pretreatment serum biomarker levels 
according to clinical response
For this analysis, 11 patients achieving a cCR were compared
with 12 patients demonstrating no response. Serum levels of
MMP-9 were significantly higher in patients achieving a cCR
while levels of tissue plasminogen activator inhibitor 1 (tPAI-1)
were significantly lower in the same group (P < 0.05, Figure
1 a ) .  H i g h e r  l e v e l s  o f  I L - 6  a n d  I L - 8  w e r e  a l s o  o b s e r v e d  i n
patients achieving a cCR, although this observation was not
statistically significant (P < 0.07, Figure 1).
A CART classification tree analysis of serum biomarker levels
from these patients identified a three-biomarker panel consist-
ing of α-fetoprotein, soluble vascular cell adhesion molecule 1,
and MMP-9 that could distinguish between the response
groups with 83% sensitivity and 91% specificity (Table 3).
Interestingly, when the 11 patients achieving a cCR were com-
bined with 19 patients achieving a clinical partial response and
were compared with the nonresponders, tPAI-1 alone could
distinguish responders from nonresponders with 75% sensi-
tivity and 77% specificity (Table 3 and Figure 1d). Serum lev-
els of tPAI-1 were significantly lower in responders (cCR and
clinical partial response) compared with nonresponders (P <
0.007, Figure 1b).
Analysis of serum biomarker levels according to clinical 
response prior to the second cycle of neoadjuvant 
chemotherapy
For this analysis, 11 patients achieving a cCR were compared
with 11 patients demonstrated no response. Serum levels of
IL-8 were significantly higher and those of insulin-like growth
factor binding protein 1 were significantly lower in patients
achieving a cCR (P < 0.05, Figure 1c). CART classification
tree analysis of serum biomarker levels from these patients
identified a three-biomarker panel consisting of MMP-3,
luteinizing hormone, and thyroid stimulating hormone that
could distinguish between clinical response groups with 82%
sensitivity and 73% specificity (Table 3).
Table 2
Complete list of biomarkers tested
Biomarker category Individual biomarkers
Cancer antigens/oncogenes α-Fetoprotein, CA 125, CA 19-9, CA 15-3, CA 72-4, carcinoembryonic antigen
Cytokines/chemokines/receptors Eotaxin, fractalkine, granulocyte–macrophage colony-stimulating factor, IFNγ, IL-10, IL-12p70, IL-13, IL-1β, IL-
1Rα, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-6R, IL-7, IL-8, IP-10, migration inhibitory factor, MIP-1β, soluble CD40L, 
TNFα, TNF-R1, TNF-R2
Growth/angiogenic factors Epidermal growth factor receptor, ErbB2, insulin-like growth factor binding protein 1, transforming growth 
factor alpha
Proteases Kallikrein 10, MMP-2, MMP-3, MMP-9
Hormones Adrenocorticotropic hormone, follicle-stimulating hormone, growth hormone, luteinizing hormone, prolactin, 
thyroid-stimulating hormone
Adipokines Adiponectin
Apoptosis-related molecules Cyfra 21-1, DR5, soluble Fas, soluble Fas ligand
Metastasis-related molecules Myeloperoxidase, tissue plasminogen activator inhibitor 1
Adhesion molecules Soluble intracellular adhesion molecule 1, soluble vascular cell adhesion molecule 1
Other proteins HE4, mesothelinAvailable online http://breast-cancer-research.com/content/10/3/R45
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Analysis of serum biomarker levels according to 
pathologic response prior to the second cycle of 
neoadjuvant chemotherapy
For this analysis, 27 patients achieving a pCR or pathologic
partial response were compared with 16 patients demonstrat-
ing no response. Serum levels of EGFR, soluble Fas ligand,
migration inhibitory factor (MIF), and MMP-2 were significantly
higher in responders compared with non-responders (P  <
0.05, Figure 2a).
A logistic regression analysis of the serum biomarker levels in
these patients identified a five-biomarker panel consisting of
ErbB2, EGFR, MIF, MMP-2, and CD40L that could distinguish
responders from nonresponders with 85% sensitivity and
69% specificity (Table 3 and Figure 2b).
Discussion
The heterogeneity displayed by patients diagnosed with
LABC runs counter to the rationale for generalized treatment
regimens. A wide array of treatment options exist for the treat-
ment of breast cancer – including adjuvant and NAC, hormone
therapy, radiotherapy, and surgery – and the vast majority of
these options have been well researched. The ability to dynam-
ically tailor the components of a particular treatment regimen
on a patient by patient basis would be invaluable. Such an
accomplishment will require the identification and develop-
Figure 1
Serum biomarker analysis of neoadjuvant chemotherapy for locally advanced breast cancer according to clinical response Serum biomarker analysis of neoadjuvant chemotherapy for locally advanced breast cancer according to clinical response. (a) Pretreatment serum 
levels of IL-6, IL-8, MMP-9, and tissue plasminogen activator inhibitor 1 (tPAI-1) were compared between 11 patients achieving a clinical complete 
response (cCR) and 12 patients demonstrating no response (NR) to neoadjuvant chemotherapy (NAC). (b) Pretreatment serum levels of tPAI-1 
were compared between 30 patients achieving a cCR or clinical partial response (cPR) and 12 patients demonstrating NR to NAC. (c) Serum levels 
of insulin-like growth factor binding protein 1 (IGFBP-1) and IL-8 measured prior to the second round of NAC were compared between 11 patients 
achieving a cCR and 11 patients demonstrating NR to NAC. (d) Cumulative receiver operating characteristics for responders versus nonresponders 
based on pretreatment serum levels of tPAI-1. Statistical significance: *P < 0.05; **P < 0.01.
Table 3
Predictive power of multimarker panels
Panel Timepoint Response type Sensitivity (%) Specificity (%)
α-Fetoprotein, soluble vascular cell adhesion 
molecule 1, MMP-9
Pretreatment Clinical complete response versus no 
response
83 91
Tissue plasminogen activator inhibitor 1 Pretreatment Clinical complete response/clinical partial 
response versus no response
75 77
MMP-3, luteinizing hormone, thyroid-stimulating 
hormone
Pre-cycle 2 Clinical complete response versus no 
response
82 73
ErbB2, epidermal growth factor receptor, 
migration inhibitory factor, MMP-2, CD40 ligand
Pre-cycle 2 Pathologic complete response/pathologic 
partial response versus no response
85 69Breast Cancer Research    Vol 10 No 3    Nolen et al.
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ment of improved prognostic factors on which to base thera-
peutic decisions, since currently used measurements of
clinical and radiological response lack the necessary preci-
sion. In the present article we demonstrate the predictive value
of serum biomarkers for the response to NAC for LABC. The
diverse nature of the biomarker relationships identified in the
study underscores the diversity of the disease characteristics
present in the patient population.
Previous studies have examined the value of biomarkers such
as carcinoembryonic antigen, CA 15-3, MMP-2, MMP-9, tis-
sue polypeptide antigen (TPA), tissue polypeptide-specific
antigen (TPS), EGFR, and HER-2/neu in predicting response
to NAC for breast cancer [33-36]. The results of these inves-
tigations have been mixed. To our knowledge, the panel of
serum biomarkers examined in the present study is the largest
and most diverse to date and the majority of the relationships
we identify have not been described previously.
Our results indicate that elevated serum levels of IL-6, IL-8,
and MMP-9 prior to the initiation of treatment correlate with
improved clinical response. The observed increases in IL-6
and IL-8 serum levels of 2.74 and 3.13 pg/ml, respectively
(Figure 1a), were not significant in our study given the limited
23-patient enrollment. Utilizing these data, we predict that an
enrollment of 59 patients would be sufficient to confer signifi-
cance (P < 0.05) upon these observations with a power of 0.9.
Increased serum levels of the inflammatory cytokines IL-6 and
IL-8 have been associated with poor prognosis in women with
breast cancer [37,38]. These cytokines have also been impli-
cated in the blood-borne response to paclitaxel treatment [39].
The prognostic value of MMP-9 serum levels is currently
unclear [33], but several studies have examined extensively
the role of matrix metalloproteinases in breast cancer [40,41].
Our results also demonstrate a correlation between lower pre-
treatment serum levels of tPAI-1 and improved clinical
response. In fact, tPAI-1 levels alone were able to discriminate
responders from nonresponders with 75% sensitivity and
77% specificity prior to the start of NAC. tPAI-1 is a major
physiological inhibitor of tissue-type plasminogen activators
and has been implicated in tumor growth, invasion, and angio-
genesis. The function of tPAI-1 as a regulator of plasminogen
activation places it in a position to modulate degradation of the
extracellular matrix and antiangiogenic effects mediated by
plasmin and angiostatin, respectively. Several groups have
illustrated experimentally the role of tPAI-1 in tumor progres-
sion and its negative prognostic value in breast cancer [42-
44].
In sera collected after patients had received the initial cycle of
chemotherapy we observed that increased levels of IL-4, IL-8,
and adrenocorticotropic hormone and decreased levels of
insulin-like growth factor binding protein 1 all correlated with
improved clinical response at differing levels of significance.
The increase in levels of inflammatory cytokines following
Figure 2
Serum biomarker analysis of neoadjuvant chemotherapy for locally advanced breast cancer according to pathologic response Serum biomarker analysis of neoadjuvant chemotherapy for locally advanced breast cancer according to pathologic response. (a) Serum levels of 
epidermal growth factor receptor (EGFR), soluble Fas ligand (sFasL), migration inhibitory factor (MIF), and MMP-2 measured prior to the second 
round of neoadjuvant chemotherapy (NAC) in 27 patients achieving a pathologic complete response (pCR) or partial pathologic response (pPR) and 
16 patients demonstrating no response (NR) to NAC. (b) Cumulative receiver operating characteristics for patients achieving a pCR or pPR versus 
nonresponders to NAC based on serum levels of ErbB2, EGFR, MIF, MMP-2, and CD40 measured prior to the second cycle of NAC. Statistical sig-
nificance: *P < 0.05.Available online http://breast-cancer-research.com/content/10/3/R45
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chemotherapy is in line with clinical expectations and is evi-
dence that the therapeutic agents are active in the patient's
system. The roles of the insulin-like growth factor system and
hormones in the response to chemotherapy have not been sig-
nificantly evaluated; however, both groups have known roles in
the development of breast cancer [45,46].
With regards to pathologic response, we observed a correla-
tion between increased levels of soluble Fas ligand, MMP-2,
MIF, and EGFR and improved response. A proapoptotic
response following chemotherapy, as evidenced by increased
soluble Fas ligand in the sera, is to be expected. Our observa-
tion of increased levels of MMP-2 in the sera of responders
supports the notion of matrix metalloproteinase involvement in
breast cancer. The precise role of macrophage MIF in breast
cancer development and treatment response remains
unknown, but MIF has been implicated in tumor cell survival
pathways [47]. The value of EGFR serum and tissue levels in
predicting response to chemotherapy has been examined pre-
viously with inconclusive results [43,48]. Increased expression
of EGFR has been demonstrated elsewhere to suggest a poor
prognosis in breast cancer [49].
It is noteworthy to mention that our present analysis did not
identify any significant relationships between CA 15-3 or
HER2/Neu and response to NAC. This observation adds to
several sparse and conflicting reports in the literature
[23,50,51]. It would appear from this uncertainty that,
although these particular biomarkers have shown the most
promise in terms of diagnosis and prognosis of breast cancer,
they may not offer predictive power for chemotherapy
response.
In addition to the individual serum biomarkers found to be sig-
nificant at each timepoint, our multivariate analysis of the data
identified several multimarker panels with predictive value for
both clinical response and pathologic response prior to or
early in the course of treatment. These multimarker panels
demonstrated greater predictive power than any single
biomarker and illustrate the potential clinical utility of this type
of approach to the design and maintenance of treatment regi-
ments. Previous studies from our group have demonstrated
the usefulness of multimarker panels in the early detection of
ovarian cancer, endometrial cancer, and head and neck can-
cers [27,52,53].
Conclusion
Our relatively small study population limits the predictive
power of the panels presented here, but the benefits of a
serum biomarker and multimarker approach are clearly illus-
trated and further studies utilizing larger clinical cohorts, as
discussed above, are well warranted. As we increase our
knowledge of the biomarkers involved in these panels and
continue to identify additional players, our ability to utilize the
information we receive from exploratory investigations such as
this will increase immensely. Continuing efforts in line with
those presented here should bring us closer to providing
effective and efficient individualized treatment to women diag-
nosed with this challenging disease.
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